On this page
Enhertu
fam-trastuzumab deruxtecan-nxki
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Enhertu
Proper name
fam-trastuzumab deruxtecan-nxki
Licence type
351(a)
BLA number
761139
Applicant
Daiichi Sankyo, Inc
Center
CDER
Presentations
1
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 100MG | For Injection | Intravenous | Single-Dose Vial | Rx | December 20, 2019 |
Exclusivity
Source: Purple Book| Kind | Expires |
|---|---|
| Orphan exclusivity | January 15, 2028 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |